AT
ATRC.US AtriCure Inc
- Market cap
- USD 2.89B
- P/E
- 183.4x
- P/B
- 5.34x
- ROE
- 3.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ATRC.US undervalued?
Graham numberThe Graham number of AtriCure Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AtriCure Inc fundamental analysis
No fundamental analysis for AtriCure Inc yet.
AtriCure Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AtriCure Inc
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF prod…
Full company profileAtriCure Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AtriCure Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 155M | 175M | 202M | 231M | 207M | 274M | 330M | 399M | 465M | 535M | 599M |
| Gross Profit | 111M | 126M | 147M | 170M | 149M | 206M | 246M | 300M | 348M | 398M | 463M |
| Operating Income | -31.1M | -25.0M | -17.1M | -33.1M | -44.2M | 55.2M | -42.7M | -26.7M | -40.0M | -3.45M | 19.4M |
| EBITDA | -22.2M | -15.5M | -7.55M | -21.5M | -34.7M | 65.7M | -31.0M | -8.11M | -18.5M | 16.2M | 40.3M |
| Net Income | -33.3M | -26.9M | -21.1M | -35.2M | -48.2M | 50.2M | -46.5M | -30.4M | -44.7M | -11.4M | 17.5M |
| EPS | -1.05 | -0.83 | -0.62 | -0.94 | -1.14 | 1.09 | -1.02 | -0.66 | -0.95 | -0.24 | 0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 276M | 268M | 357M | 558M | 715M | 615M | 585M | 614M | 609M | 654M | 718M |
| Total Liabilities | 108M | 107M | 107M | 311M | 302M | 132M | 129M | 148M | 148M | 162M | 184M |
| Shareholders' Equity | 168M | 161M | 249M | 247M | 412M | 484M | 457M | 466M | 461M | 492M | 533M |
| Cash & Short-term Investments | 44.0M | 34.5M | 124M | 81.8M | 244M | 119M | 121M | 137M | 123M | 167M | 187M |
| Total Debt | 38.9M | 37.4M | 52.5M | 76.4M | 74.0M | 75.6M | 74.5M | 74.5M | 76.5M | 88.0M | 93.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.1M | -8.94M | -4.17M | -15.8M | -19.9M | -13.8M | -22.1M | 4.48M | 12.2M | 57.3M | 64.7M |
| Capital Expenditure | 7.69M | 6.38M | 6.21M | 12.2M | 5.26M | 9.75M | 16.9M | 42.0M | 23.5M | 9.05M | 18.7M |
| Free Cash Flow | -22.8M | -15.3M | -10.4M | -28.0M | -25.1M | -23.5M | -39.0M | -37.5M | -11.3M | 48.3M | 46.0M |
| Ratios | |||||||||||
| ROE | -19.8% | -16.7% | -8.5% | -14.2% | -11.7% | 10.4% | -10.2% | -6.5% | -9.7% | -2.3% | 3.3% |
| ROA | -12.1% | -10.0% | -5.9% | -6.3% | -6.7% | 8.2% | -7.9% | -5.0% | -7.3% | -1.7% | 2.4% |
| Net Profit Margin | -21.5% | -15.4% | -10.5% | -15.2% | -23.3% | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% | 2.9% |
| Debt to Equity | 0.23x | 0.23x | 0.21x | 0.31x | 0.18x | 0.16x | 0.16x | 0.16x | 0.17x | 0.18x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AtriCure Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 60.0K | 0.00 | - |
| 2022 | USD 6.04M | 0.13 | - |
| 2021 | USD 12.4M | 0.27 | 24.6% |
| 2020 | USD 14.2M | 0.34 | - |
| 2019 | USD 3.86M | 0.10 | - |
| 2018 | USD 25.8M | 0.76 | - |
| 2017 | USD 4.40M | 0.14 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AtriCure Inc
- Insiders 3.73%
- Institutions 96.27%
- Public & others 0.00%
- Shares outstanding 50.9M
- Free float 48.9M
Top funds holding ATRC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3.06M | 6.01% | -0.09% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.53M | 3.00% | +0.36% | Sep 2026 |
| Hood River Small-Cap Growth Instl | 1.53M | 3.00% | -6.76% | Jun 2026 |
| Nomura Small Cap Core I | 1.28M | 2.51% | -7.43% | Sep 2026 |
| iShares Russell 2000 ETF | 1.26M | 2.48% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.09M | 2.14% | -1.58% | Sep 2026 |
| AB Discovery Growth A | 742K | 1.46% | -5.00% | Sep 2026 |
| AB Small Cap Growth A | 713K | 1.40% | -9.68% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 606K | 1.19% | -4.41% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 569K | 1.12% | +0.27% | Oct 2026 |
| Fidelity Small Cap Index | 546K | 1.07% | +0.18% | Aug 2026 |
| BNP Paribas US Small Cap ClassicC | 487K | 0.96% | -8.52% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 468K | 0.92% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 465K | 0.91% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 458K | 0.90% | -0.26% | Oct 2026 |
| GS Glb Sm Cp CORE Eq Base Inc USD Snap | 437K | 0.86% | +1.05% | Aug 2026 |
| Champlain Small Company Adv | 383K | 0.75% | -13.35% | Jun 2026 |
| BNP Paribas Health Cr Innovtr Cl Cap | 334K | 0.66% | -8.33% | Sep 2026 |
| Vanguard Strategic Equity Inv | 313K | 0.61% | +7.19% | Sep 2026 |
| EQ/AB Small Cap Growth IB | 302K | 0.59% | -5.08% | Sep 2026 |
Top institutions holding ATRC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.47M | 8.79% | +10.68% | Jun 2026 |
| Wellington Management Company LLP | 3.50M | 6.87% | +3.34% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.13M | 6.14% | +15.71% | Jun 2026 |
| Hood River Capital Management LLC | 2.91M | 5.71% | -6.81% | Jun 2026 |
| AllianceBernstein L.P. | 2.77M | 5.44% | -15.05% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.19M | 4.30% | +1.61% | Jun 2026 |
| Delaware Management Holdings Inc | 1.73M | 3.41% | -3.91% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.60M | 3.14% | -4.15% | Jun 2026 |
| State Street Corp | 1.39M | 2.73% | +6.74% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.33M | 2.62% | -9.11% | Jun 2026 |
| Geode Capital Management, LLC | 1.32M | 2.59% | +7.63% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.30M | 2.55% | +366.80% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.02M | 2.01% | -2.19% | Sep 2026 |
| GW&K Investment Management, LLC | 950K | 1.87% | -1.44% | Jun 2026 |
| Neuberger Berman Group LLC | 948K | 1.86% | -9.74% | Jun 2026 |
| Champlain Investment Partners, LLC | 939K | 1.84% | -3.35% | Jun 2026 |
| BNP Paribas Investment Partners SA | 897K | 1.76% | -15.40% | Jun 2026 |
| Bank of America Corp | 874K | 1.72% | +13.77% | Jun 2026 |
| Kennedy Capital Management Inc | 858K | 1.68% | +2.83% | Jun 2026 |
| Divisadero Street Capital Management, LP | 801K | 1.57% | -30.95% | Jun 2026 |
AtriCure Inc company profile
- Company name
- AtriCure Inc
- Ticker
- ATRC.US
- Exchange
- USA Stocks
- Listed since
- Aug 5, 2005
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,350
- Fiscal year end
- December
- Address
- 7555 Innovation Way, Mason, OH, United States, 45040
- Phone
- 513 755 4100
- Website
- atricure.com
About AtriCure Inc
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
AtriCure Inc management
8- Mr. Michael H. CarrelCEO, President & Director · born 1971
- Ms. Angela L. WirickChief Financial Officer · born 1978
- Mr. Douglas J. SeithChief Operating Officer · born 1966
- Mr. Salvatore Privitera J.D.Chief Technical Officer · born 1967
- Mr. Justin J. NozneskyChief Marketing & Strategy Officer · born 1978
- Dr. Vinayak Doraiswamy Ph.D.Chief Scientific Officer · born 1973
- Mr. Karl S. Dahlquist CCEP, J.D.Chief Legal Officer · born 1971
- Valerie Storch-WillhausVice President of Corporate Marketing & Communications